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Whole brain radiation therapy (WBRT) is an effective treatment in brain metastases and, when combined with local
treatments such as surgery and stereotactic radiosurgery, gives the best brain control. Nonetheless, WBRT is often
omitted after local treatment due to its potential late neurocognitive effects. Publications on radiation-induced
neurotoxicity have used different assessment methods, time to assessment, and definition of impairment, thus
making it difficult to accurately assess the rate and magnitude of the neurocognitive decline that can be expected.
In this context, and to help therapeutic decision making, we have conducted this literature review, with the aim of
providing an average incidence, magnitude and time to occurrence of radio-induced neurocognitive decline. We
reviewed all English language published articles on neurocognitive effects of WBRT for newly diagnosed brain
metastases or with a preventive goal in adult patients, with any methodology (MMSE, battery of neurcognitive tests)
with which baseline status was provided. We concluded that neurocognitive decline is predominant at 4 months,
strongly dependant on brain metastases control, partially solved at later time, graded 1 on a SOMA-LENT scale (only
8% of grade 2 and more), insufficiently assessed in long-term survivors, thus justifying all efforts to reduce it through
irradiation modulation.
Keywords: Neurocognitive impairment, Whole brain radiation therapy, Brain metastasesIntroduction
Neurocognitive effect of whole brain radiation therapy
(WBRT) is a crucial problem since fear has led physicians
to postpone this effective treatment for patients with
oligometastic brain metastases (BM) after local treatment
(stereotactic radiosurgery (SRS) or surgery), despite its
ability to reduce intracranial failure and neurologic death
rates [1-3]. This seems detrimental, especially in patients
for whom extra-cranial disease is absent or controlled and
the primary tumor radiosensitive. Indeed, in situations
of controlled extra-cranial disease, the objective of the
treatment of newly diagnosed BM is not only to palliate
symptoms, but also and mainly to control BM, and thus* Correspondence: talleta@ipc.unicancer.fr
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reproduction in any medium, provided the oran aggressive approach is required. This is all the more
important since, while randomized controlled trials (RCT)
evaluating the omission of up-front WBRT did not show a
difference in overall survival [1-3], some retrospective
trials concerning patients without extra-cranial disease,
have shown the opposite [4,5].
Determining the impact of WBRT on neurocogni-
tive function (NCF) would provide support for thera-
peutic decision making for individual patient, for
which we need to elucidate the incidence, time
course, intensity, domains of neurocognitive changes
following WBRT and their actual impact on patient
quality of life (QOL). There is a paucity of data on
neurocognitive impairment after WBRT, which has
previously been assessed using various different
neuropsychological tests, as well as different defini-
tions of neurocognitive impairment. It is noteworthy
that NCF is affected by a number of factors (i.e. BM
volume, disease progression [intra and/or extra-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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surgery, radiation, prior neurologic disease, medica-
tions, paraneoplastic effects, etc.) which should be
considered when evaluating of the actual neurocogni-
tive effect of treatments such as WBRT.
The objective of this review was to obtain accurate
data regarding neurocognitive impairment after
WBRT and to objectively include them in decision
making at time of BM onset. We carried out a litera-
ture review of NCF tools used and their results.
Before the year 2000, most studies concerning the
neurocognitive effects of WBRT were retrospective,
thus without neurocognitive assessment by validated
tests or without reliable baseline evaluation. These
studies revealed potential dementia, and/or imaging
changes [6-9].
Since 2003, neurocognitive tests have been included in
RCT, however, the real impact of WBRT on NCF
remains unclear because of the variability in time to as-
sessment, definition of neurocognitive impairment, pa-
tient population, radiation doses and especially dose per




We carried out a literature review and analysed all
English language published articles on neurocognitive
effects of WBRT alone (without any concurrent treat-
ment) for newly diagnosed BM or with preventive goal
in adult patients, in either a prospective or retrospect-
ive setting, whatever the methodology used (Mini-
Mental State Examination (MMSE) [10], battery of
neurcognitive tests as described by Meyers and Brown
[11]) provided there was a baseline assessment and
results were compiled.
We conducted a systematic search using the Med-
line database up to September 2011. Eligible studies
investigated WBRT in one of the study arm. The term
“neurocognitive function” combined with the terms “ir-
radiation” and “brain metastases” were used. Relevant
articles were reviewed, and the reference lists from these
sources were manually searched for additional relevant
trials.
Articles were excluded from this literature review if
they were individual case reports or review articles.
Data extracted from studies included: number of
patients accrued and evaluated in the WBRT arm of
the study, radiation therapy schedule, disease status
when available, neurocognitive tests used, definition
of neurocognitive impairment, time of assessment,
percentage of patients who experienced a neurocogni-
tive decline. Data extracted from text, tables and figures of
the articles were then tabulated.Results
We identified 16 articles reporting 12 trials assessing
the neurocognitive outcome of patients treated with
WBRT alone (6 based on the MMSE, 9 on a battery of
validated neurocognitive tests, and one using the EORTC-
Radiation Therapy Oncology Group [RTOG] Late Effects
Normal Tissue [LENT]-Subjective, Objective, Manage-
ment, analytic [SOMA] LS scale). Two of these articles
assessed the neurocognitive impairment of WBRT follow-
ing SRS. One of them used the MMSE as NCF assessment
tool [12], the second was the only RCT to have neurocog-
nitive outcome as primary end-point [13].
Assessment on MMSE
The initial assessments of neurocognitive impairment
after WBRT were based on MMSE measurement, both
in therapeutic cranial irradiation (TCI) (4 studies), and
in prophylactic cranial irradiation (PCI) (1 study).
Neurocognitive outcome after TCI (BM present)
The impact of fractionation schedule (accelerated
hyperfractionation vs. standard accelerated fractionation
WBRT) was analysed in a phase III study from the RTOG
[14]. The primary end-point was overall survival. Murray
et al., and Regine et al., evaluated the MMSE in 182
patients with BM enrolled in the accelerated fractionation
arm (30 Gy/10 fractions) [15,16]. The authors found that
54.5% of patients experienced an improvement in their
MMSE at any follow-up visit. At two and three months,
29% and 16% of patients respectively with pretreatment
MMSE 28 to 30 experienced a decline. For patients with
pretreatment MMSE <28, an improvement in MMSE was
observed in 42% of patients at two months, 33% at three
months, the MMSE was stable in 28% at two months, 18%
at three months, and declined in 28% of patients at two
months, and 46% at three months [16] (Table 1). Only the
neurocognitive outcome of patients in the accelerated
fractionation arm was extracted from these reports, but
no difference was found between the two arms. It is note-
worthy that a clinically/statistically meaningful drop in
MMSE at two and three months was only observed in
patients with uncontrolled BM. The authors pointed out
the limitations of their secondary analysis due to the poor
survival of the patient population, and thus the evaluation
of neurocognitive effects of WBRT was restricted to the
short term.
The incidence of brain atrophy and decline in MMSE
after WBRT [40 Gy in 20 fractions with (72% of patients)
or without a 10 Gy boost] was prospectively described in
92 patients with BM [17]. A decrease in MMSE scores
of ≥ 4 points was observed in 7.4%, 11%, 20%, 12%,
5.9% of assessable patients at 3, 6, 9, 12, and 15 months
respectively, and no decrease in MMSE was observed
thereafter (last assessment: 36 months) (Table 1). This was
Table 1 Neurocognitive impairment after WBRT as assessed by MMSE
Study N Radiation scheme Brain
control
Assessment time
% of patients impaired
2month 3mo 6mo 12mo 18mo
Regine et al., 2001 182 30 Gy/10 fractions/12 Yes 0 0 NR NR NR
[16] days (TCI) No 28 46
Shibamoto et al., 2008 [17] 92 40 Gy/20 fractions/33 days (TCI) Yes NR 7.4 11 12 0
Corn et al., 2008 [18] 92 37.5 Gy/15fractions/19 days (TCI) Yes 18 24 24 28 28
No 23 23 33 38 40
Aoyama et al., 2007 [12] 41 30 Gy/10 fractions/12 days (TCI) NR 5 a 16a 16 a 28 a 40 a
2 b 10 b 14 b 21 b 21 b
5 c 14 c 16 c 24 c 24 c
Sun et al., 2011 [19] 340 30 Gy/15 fractions/19 days (PCI) NR NR 36 28 23 NR
Only studies from which percentages of patients impaired on NCF could be extracted are reported in this table. WBRT =Whole Brain Radiation Therapy;
TCI = Therapeutic Cranial Irradiation; PCI = Prophylactic Cranial Irradiation; NR = not reported; a = patients who underwent a 3-point decrease in MMSE; b = patients
who underwent a decrease of MMSE ≤ 26; c = patients who underwent a 3-point decrease in MMSE, excluding those who return to their initial MMSE.
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progression were excluded from the evaluation but
patients with systemic progressive disease were included,
and about half the patients with an MMSE score decrease
had systemic progression and a decrease in performance
status.
The efficacy of Thalidomide (a putative antiangiogenic
agent) concurrently administered with WBRT was
assessed in a phase III trial for 156 adult patients with
multiple BM [18]. In 92 patients of the WBRT alone
arm, the neurocognitive effect of WBRT (37.5 Gy in
fractions of 2.5 Gy) was investigated. As shown in Table 1,
28% of patients with brain disease control experienced a
neurocognitive decline at one year (but the magnitude of
this decline was not given), while 38% of patients with
intra-cranial progression showed a drop in MMSE scores
from baseline.
Efficacy of WBRT added to SRS at initial treatment of
newly diagnosed BM was investigated in a RCT from
Aoyama et al.[1] The authors subsequently reported on
the NCF deterioration rate of 36 patients (with initial
MMSE ≥ 27) enrolled in the WBRT plus SRS arm [12].
The authors assessed the MMSE deterioration every
3 months, and recorded the percentage of patients who
experienced a drop in MMSE score at least once, unless
they recovered subsequently their initial MMSE, the per-
centage of patients impaired at a specified time, and the
percentage of patients who experienced a decrease of
MMSE ≤ 26 on at least one occasion. The results are
presented in Table 1. Interestingly, no statistically signifi-
cant difference was observed between patients treated
with WBRT and SRS and those treated with SRS alone,
despite a difference in the time to deterioration, which was
longer for the combined treatment group (> 12 months
for the WBRT+SRS group vs< 8 months for the SRS
group, p=0.05)). Finally, while a quarter of patientsexperienced a drop in MMSE at 12 months, this percent-
age worsened over time, indicating that WBRT is effective
at preventing the neurocognitive decline resulting from
brain tumor recurrence in the first 2 years, but could be a
cause of continuous deterioration of NCF in long-term
survivors.
Neurocognitive outcome after PCI (no BM)
The effect of prophylactic cranial irradiation (PCI) on
NCF and QOL was assessed by Sun et al. [19] in 64
patients with small cell lung cancer (SCLC) without BM
and without disease progression after completing defini-
tive therapy. NCF was assessed with MMSE, and Hopkins
Verbal Learning Test (HVLT), using the Reliable Change
Index (RCI) method [20]. One third of patients experi-
enced a decline in MMSE score 3 months after comple-
tion of PCI, while 28% and 23% were impaired on the
same test at 6 and 12 months respectively (Table 1).
Moreover, no significant difference in MMSE (except at
3 months) was observed at 1 year when comparing
patients submitted to PCI and those without PCI.
Conversely, the HVLT was more often impaired at
1 year in the PCI arm, with an average of 30% of patients
impaired at 1 year (compared to 6% of patients in the
observation arm), which is less than the impairment
observed at 3 months (Table 2). The authors were unable
to separate those patients who did or did not develop BM,
due to the small number of events.
Assessment on a battery of validated neurocognitive
tests
A report by Meyers and Brown, to identify the optimal
battery of neurocognitive tests to use for patients with cen-
tral nervous system disease, did not recommended the use
of brief mental status evaluation, which only detect signifi-
cant dementia and have extremely poor sensitivity in
Table 2 Time, NCF domain impaired, and incidence of NC impairment after WBRT
Study
Radiation scheme Nb Assessment time Domains
impaired
Impairment
definition% of patients impaired
1 mo 2 mo 3 mo 5 mo 12 mo
Sun et al.,
2011 [19]
PCI 30Gy/15 fr 163 §HVLT
_ _ 45% 26% Recall
44% 32% Delayed recall
Meyers et al.,
2004 [22]
30 Gy/ 10fr ± MGd 401 _ _ 31% _ *Pegboard >2 DS
7% †COWA >2 DS
30Gy/10fr alone 208 48% §HVLT ≥ 4.5 DS












TCI: 40Gy/20fr 16 9% _ _ _ §MCG RCI (≥1score)




57% _ _ _ §AVLT RCI (≥1score)
PCI: 36Gy/18fr 13 23% _ _ _ §MCG RCI (≥1score)




44% §AVLT RCI (≥1score)
_



















36 Gy/18 fr 67 85%
36 Gy/twice-daily 24fr 66 89%
Only studies from which percentages of patients impaired on NCF could be extracted are reported in this table. PCI = Prophylactic Cranial Irradiation; MGd =
Motexafin Gadolinium; *Pegboard: grooved pegboard test, examining motor speed and dexterity; †COWA: Controlled Oral Word Association, test examining verbal
fluency; § HVLT: Hopkins Verbal Learning Test, examining immediate recall, delayed recall, and recognition; MCG: Medical College of Georgia Complex Figures,
examining visual memory and visual construction (copy, immediate recall and delayed recall); AVLT: Auditory Verbal Learning Test, examining verbal memory;
‡TMT-A and B: trailmaking test A, examining visual-motor scanning speed, and B, examining executive functions.
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patients [11].
Neurocognitive outcome after TCI (BM present)
The effect of Motexafin Gadolinium (MGd) combined with
WBRT (30 Gy given in 10 daily fractions) was evaluated in
401 patients with BM in a multi-institutional phase IIIstudy [21-23]. The co-primary end-points were survival
and time to neurologic progression. As a secondary end-
point, the authors evaluated the time to neurocognitive
progression. The WBRT alone arm included 208 patients,
and their neurocognitive outcome was analysed (Table 2).
Findings from these reports were: (1) nearly all patients
(90.5%) with multiple metastases (80.1%) had some
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pairment of one or more neurocognitive tests), 42,4% hav-
ing an impairment in four or more tests; (2) this baseline
impairment of neurocognitive function was highly
correlated to the volume of the indicator lesion at baseline;
(3) patients progressed most in pegboard (fine motor) per-
formance at three months; (4) at four months, there was a
sharp drop in the mean NCF scores, mainly in memory
function, while at 15 months, the mean NCF test scores
gradually improved, especially in verbal fluency, executive
function and fine motor coordination, but not memory;
(5) at 12 months, 48% of surviving patients treated by
WBRT alone (with or without progressive disease) had
impaired HVLT and Controlled Oral Word Association
Test (COWAT); (6) median time to NCF deterioration for
all eight tests was longer in good responders than in poor
responders (p= 0.008), especially for executive function
and fine motor coordination.
Chang et al. described the only RCT with NCF as pri-
mary end-point [13]. Patients with 1–3 BM were ran-
domly assigned to SRS alone (30 patients) or SRS plus
WBRT (28 patients). The RCI was used to measure mean-
ingful change between baseline and four months for the
different tests used; a decline was declared if there was a
decline in the total recall score of ≥5 points compared
with baseline. The trial was halted by the data monitoring
committee according to the early rules on the basis that
total recall at 4 months for SRS +WBRT group was infer-
ior to SRS alone group. Of the patients receiving com-
bined treatment, 64% experienced a decline in total recall
tests. Extensive discussions of these results highlighted
several shortcomings [24,25], and no definite conclusions
could be drawn. In particular, patients in the combined
treatment group had a surprisingly, unexplained short me-
dian survival which could have had an impact on NCF
tests and time of assessment is debatable, since a transi-
ent effect on memory following WBRT has already been
proved, with a nadir at 4 months [26].
Welzel et al. published a prospective evaluation of neu-
rocognitive effect of WBRT for 44 patients with or without
BM, irradiated prophylactically (PCI: 13 patients) or for
therapeutic effect (TCI: 16 patients), compared with a
control group irradiated on the breast (15 patients) [27].
Patients were described as improved, stable or impaired
on NCF using the RCI method. NCF was assessed at
baseline, at the “acute phase” (after starting radiotherapy
and at its completion), and at the “subacute phase”
(at 6–8 weeks after radiotherapy) (Table 2). Approxi-
mately one third of the TCI and PCI patients had
cognitive impairment on at least two subsets even be-
fore treatment. At the end of radiotherapy, almost all
verbal memory scores had improved or returned to
the baseline level. Declines in visual memory were
balanced by improvements. The authors concludedthat cognitive dysfunction after WBRT restricted to verbal
memory.Neurocognitive outcome after PCI (no BM)
The studies from Van Oosterhout et al. [28], Komaki et al.
[29], Grosshans et al. [30], evaluating the neurocognitive
outcome of patients subjected to PCI included few patients
and the results lacked of precision. Thus, the data from
these studies were not detailed, but it was noteworthy that
the authors did not observe any consistent neurocognitive
impairment after PCI (Table 2).
Impact of different total dose and schedule of PCI on
neurologic deterioration was analysed by Wolfson et al.
for 264 patients with limited-disease SCLC [31]. Patients
who achieved a complete response after chemotherapy
and thoracic irradiation, without evidence of brain dis-
ease on imaging were randomized to one of the three
arms of PCI (25 Gy/10 fractions or 36 Gy/18 fractions or
36 Gy/twice-daily 24fractions). The NCF assessment (co-
primary end-point) was performed at baseline, 6 months
and 12 months after randomization. Neurologic deterior-
ation was defined as a decrease of one SEM from base-
line in any of the battery of tests, and confirmed using
the RCI. More than 60% of patients receiving 25 Gy and
80-90% of those having 36 Gy PCI had documented
neurotoxicity at one year (as defined above) (Table 2).
The second co-primary end-point was QOL measured
by the EORTC QLQ-C30 and brain module (BN20).
There was no impact of this neurologic deterioration on
QOL measurements at 12 months. Moreover, the neuro-
cognitive outcome of the patients included in this series
was assessed using the LS scale [32]. LS memory decline
at 3 years was more frequent with grade 1 deficit
(decreased short term, difficulty with learning), as was
observed in 44% of patients, than grade ≥2 deficit
observed in 8% of patients without intra-cranial progres-
sive disease. The authors concluded that mild deterior-
ation of some items, such as memory, intellectual deficit
and cognitive functions possibly related to PCI, should be
balanced by considering the beneficial effects of PCI on
survival and incidence of BM.Discussion
Radio-induced neurocognitive impairment evolves in a
biphasic pattern: a subacute transient decline with a peak
at four months, and a late delayed irreversible impair-
ment of NCF several months or years after completion
of WBRT [26,33-35]. The objective of this review was
therefore to identify the incidence of these disorders in
the two phases in order to provide support for thera-
peutic decision making. The first phase is of importance
for patients with worse prognoses (due to progression of
extra-cranial disease), whereas for long-term survivors,
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therapeutic decision.
Of course, the NCF decline is not exclusively due to
WBRT, and as mentioned above, several factors may
make it worse. Moreover, pre-treatment cognitive status
(highly correlated to the volume of the disease) has
significant effects on neurocognitive outcome, as reported
by Meyers et al. [22].
Neurocognitive decline in patients without visualizable
brain disease. This literature review shows that for
patients with brain disease control, the risk of neurocog-
nitive impairment as assessed by MMSE is low (0 to 24%
of patients impaired at 3 months, 12 to 28% at one year).
A lower incidence of a drop in MMSE was observed by
Regine et al. [16], and Shibamoto et al. [17] compared to
that observed by Corn et al. [18], which may simply re-
flect the difference in defining the decline in MMSE,
which was a decrease in MMSE scores of ≥ 4 points and
a decrease of ≥ 3 points respectively for the two first pub-
lications, and only one point or more for the last. Most
studies assessing NCF in the setting of PCI (with lower
total doses and dose per fraction than therapeutic cranial
irradiation) showed very low incidence of neurocognitive
impairment at one year. This had previously been
observed in a study investigating the benefit of PCI for
non small cell lung cancer, in which neurocognitive de-
cline was assessed using a battery of neurocognitive tests
(without baseline evaluation) [36]. The authors found not
significant difference for long term survivors in patients
with or without PCI. Similar results were reported by
Arriagada et al. in a trial assessing the efficiency of PCI for
SCLC [37].
Neurocognitive decline in patients with BM present.
Based on Table 1, NCF as assessed by MMSE score is
impaired after WBRT in the year following the comple-
tion of WBRT, but appears strongly related to uncon-
trolled brain metastases. Later assessments were not
available, except in the study from Aoyama et al., which
appeared to have shown that neurocognitive decline oc-
curred continuously over time. For this reason, the
authors subsequently attempted to isolate prognostic fac-
tors for brain recurrence in patients with expected long
survival, with the objective to withhold WBRT [38,39].
They found that patients who had solitary BM in the ab-
sence of extracranial metastases were at lower risk of
brain tumor recurrence compared with patients with
multiple BMs or extracranial disease, and proposed to
postpone WBRT in those cases, given that the brain
tumor recurrence risk was 31% at 6 and 12 months in
patients at lower risk without “up-front” WBRT, allow-
ing 69% of patients to avoid unnecessary treatment.
When patients were assessed through a battery of neu-
rocognitive tests, almost half of patients were affected by
a decline, namely 31 to 57% at 3 months, and 48 to 85%at one year, depending on the definition of impairment
(Table 2).
WBRT-induced neurocognitive toxicity is to be balanced
against the neurocognitive toxicity that may cause brain
disease recurrence. Some publications describe a correlation
between brain failure and neurocognitive decline and
subsequently altered QOL [12,21-23,40,41]. These pro-
spective clinical trials demonstrate a potential benefit of
successful WBRT (i.e., achieving intracranial disease
control) on NCF-preservation [16,22]. The authors
highlighted the fact that patients who demonstrated
good radiologic response to WBRT had improved execu-
tive function and fine motor coordination, but not
memory, suggesting that WBRT might specifically im-
pair hippocampus-related functions, leading to the
concept of hippocampus avoidance during WBRT.
One RCT (from Virginia Commonwealth University)
with this objective was undertaken but unfortunately
was closed for lack of accrual (only 8 patients en-
rolled). Two phase II trial (RTOG: http://clinicaltrials.
gov/ct2/show/ NCT01227954, NCT01414738) and one
phase III trial (France: http://www.sante.gouv.fr/IMG/
pdf/resultats_PHRC_2011_cancer-2.pdf ) are ongoing.
Conclusion
Neurocognitive impairment is of concern in the setting of
WBRT delivered for BM. WBRT after local treatment (sur-
gery or SRS) allows the best brain disease control to be
obtained to date. Thus, it is necessary to minimize its late
side effects, and thereby patient enrollment in clinical trials
for WBRT needs to be expanded so that multiple methods
for avoiding and mitigating acute and late toxicities may be
developed. Local treatment alone for oligometastatic brain
disease is an option since postponing WBRT has not shown
significant impact on overall survival. The results of this re-
view will enable physicians to inform patients about bene-
fits and risks of these two treatment options.
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